Skip to content

Effect of Daily Ingestion of Drink Containing Bifidobacterium lactis (food mainly consisting of milk) on Lipid Metabolism: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group

Effect of Daily Ingestion of Drink Containing Bifidobacterium lactis (food mainly consisting of milk) on Lipid Metabolism: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group - Beneficial Effects of Drink Containing Bifidobacterium lactis on Lipid Metabolism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026643
Enrollment
54
Registered
2017-03-22
Start date
2017-03-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Daily ingestion of 100 g of drink containing Bifidobacterium lactis for 12 weeks. Daily ingestion of 100 g of drink not containing Bifidobacterium lactis for 12 weeks.

Sponsors

Hokkaido Information University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects whose LDL-C is >=120 mg/dl and <160 mg/dl. 2. Subjects who agree to participate in this study with a written informed consent.

Exclusion criteria

Exclusion criteria: 1.Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia and/or diabetes. 2.Subjects whose BMI is >=30 kg/m2 3.Subjects with familial hypercholesterolemia. 4.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 5.Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 6.Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 7.Subjects with severe anemia. 8.Pre- or post-menopausal women complaining of obvious physical changes. 9.Subjects who are at risk of having allergic reactions to drugs or foods especially based on milk or apple. 10.Subjects who regularly take medicine, functional foods, and/or supplements which would affect bowl movement. 11.Subjects who regularly take medicine, functional foods, and/or supplements which would affect the blood lipid levels. 12.Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism. 13.Heavy smokers, alcohol addicts, or subjects with eating disordered lifestyle. 14.Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 15.Pregnant or lactating women or women who expect to be pregnant during this study. 16.Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 17.Any other medical and/ or health reasons unfavorable to participation in the current study, as judged by the principal investigator.

Design outcomes

Primary

MeasureTime frame
TC, LDL-C, HDL-C, TG, LDL-C/HDL-C, and non-HDL at 4, 8, and 12 weeks after the beginning of ingestion of test food.

Secondary

MeasureTime frame
FPG, HbA1c, insulin, HOMA-IR, body weight, body fat percentage, BMI, defecation frequency

Countries

Japan

Contacts

Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026